211 related articles for article (PubMed ID: 24094519)
1. Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection.
Sun BS; Li Y; Zhang ZF; You J; Wang CL
Ann Thorac Surg; 2013 Dec; 96(6):1943-51. PubMed ID: 24094519
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection.
Yang GH; Fan J; Xu Y; Qiu SJ; Yang XR; Shi GM; Wu B; Dai Z; Liu YK; Tang ZY; Zhou J
Oncologist; 2008 Nov; 13(11):1155-65. PubMed ID: 18997126
[TBL] [Abstract][Full Text] [Related]
3. Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer.
Takenaka M; Hanagiri T; Shinohara S; Yasuda M; Chikaishi Y; Oka S; Shimokawa H; Nagata Y; Nakagawa M; Uramoto H; So T; Yamada S; Tanaka F
Clin Lung Cancer; 2013 May; 14(3):288-94. PubMed ID: 23122494
[TBL] [Abstract][Full Text] [Related]
4. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
Nguyen VN; Mirejovský T; Melinová L; Mandys V
Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
[TBL] [Abstract][Full Text] [Related]
5. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer.
Lin Q; Guo L; Lin G; Chen Z; Chen T; Lin J; Zhang B; Gu X
Cancer Epidemiol; 2015 Aug; 39(4):539-44. PubMed ID: 26123318
[TBL] [Abstract][Full Text] [Related]
6. Prognostic predictors in non-small cell lung cancer patients undergoing intentional segmentectomy.
Koike T; Koike T; Yamato Y; Yoshiya K; Toyabe S
Ann Thorac Surg; 2012 Jun; 93(6):1788-94. PubMed ID: 22560265
[TBL] [Abstract][Full Text] [Related]
7. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer.
Koike T; Koike T; Yoshiya K; Tsuchida M; Toyabe S
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):372-8. PubMed ID: 23870323
[TBL] [Abstract][Full Text] [Related]
8. Interstitial tumor-associated macrophages combined with tumor-derived colony-stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non-small cell lung cancer.
Pei BX; Sun BS; Zhang ZF; Wang AL; Ren P
J Thorac Cardiovasc Surg; 2014 Oct; 148(4):1208-1216.e2. PubMed ID: 24907005
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.
Hirata T; Fukuse T; Naiki H; Hitomi S; Wada H
Cancer Res; 1998 Mar; 58(6):1108-10. PubMed ID: 9515789
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer.
Zhang T; Zhang DM; Zhao D; Hou XM; Yang TN
J BUON; 2014; 19(3):742-8. PubMed ID: 25261661
[TBL] [Abstract][Full Text] [Related]
11. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection.
Yan CH; Lv M; Li H; Song X; Yan F; Cao S; Ren X
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1371-8. PubMed ID: 25555465
[TBL] [Abstract][Full Text] [Related]
13. Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer.
Augustin F; Fiegl M; Schmid T; Pomme G; Sterlacci W; Tzankov A
J Clin Pathol; 2015 May; 68(5):368-73. PubMed ID: 25731190
[TBL] [Abstract][Full Text] [Related]
14. [Expression and clinicopathological significance of OPN and CD44v6 in lung cancer].
Yang Y; Cheng D; Li X; Fang X
Zhongguo Fei Ai Za Zhi; 2007 Apr; 10(2):98-101. PubMed ID: 21114929
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
[TBL] [Abstract][Full Text] [Related]
16. [Multivariate survival analysis of 899 patients with non-small cell lung cancer after complete resection].
Wei WD; Wen ZS; Su XD; Lin P; Rong TH; Chen LK
Ai Zheng; 2007 Nov; 26(11):1231-6. PubMed ID: 17991324
[TBL] [Abstract][Full Text] [Related]
17. [Over-expression of osteopontin in non-small cell lung cancers: its clinical significance].
Hu Z; Xiao T; Lin DM; Guo SP; Zhang ZQ; Di XB; Cheng SJ; Gao YN
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):591-5. PubMed ID: 18210878
[TBL] [Abstract][Full Text] [Related]
18. [Establishment and evaluation of a prognostic prediction model for patients after complete resection of non-small cell lung cancer and multidisciplinary therapy].
Wei WD; Fu JH; Lin P; Li XD; Yang H; Rong TH; Chen LK
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):672-5. PubMed ID: 19173908
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic analysis of curative surgery for stage IIIA-N2 non-small cell lung cancer].
Liu JW; Li J; Lin G; Shang XQ
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):50-3. PubMed ID: 23648301
[TBL] [Abstract][Full Text] [Related]
20. Do tumours located in the left lower lobe have worse outcomes in lymph node-positive non-small cell lung cancer than tumours in other lobes?
Kudo Y; Saji H; Shimada Y; Nomura M; Usuda J; Kajiwara N; Ohira T; Ikeda N
Eur J Cardiothorac Surg; 2012 Sep; 42(3):414-9. PubMed ID: 22398463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]